Proprietary AI analyst is now available
- Public Comps
- MeiraGTx
MeiraGTx Valuation Multiples
Discover MeiraGTx's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Akums Drugs and Pharma, ACROBiosystems, TchaikaPharma, Xencor and more.
MeiraGTx Overview
About MeiraGTx
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
Founded
2018
HQ

Employees
425
Website
Financials (LTM)
EV
$980M
Valuation Multiples
Start free trialMeiraGTx Financials
MeiraGTx reported last 12-month revenue of $67M.
In the same LTM period, MeiraGTx generated $65M in gross profit and had net loss of ($138M).
Revenue (LTM)
MeiraGTx P&L
In the most recent fiscal year, MeiraGTx reported revenue of $81M and EBITDA of ($89M).
MeiraGTx is unprofitable as of last fiscal year, with gross margin of 94%, EBITDA margin of (110%), and net margin of (140%).
Financial data powered by Morningstar, Inc.
MeiraGTx Stock Performance
MeiraGTx has current market cap of $964M, and enterprise value of $980M.
Market Cap Evolution
MeiraGTx's stock price is $10.41.
MeiraGTx share price decreased by 2.3% in the last 30 days, and increased by 59.7% in the last year.
MeiraGTx has an EPS (earnings per share) of $-1.23.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $980M | $964M | 7.1% | -2.3% | 20.2% | 59.7% | $-1.23 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMeiraGTx Valuation Multiples
MeiraGTx trades at 14.7x EV/Revenue multiple, and (11.0x) EV/EBITDA.
EV / Revenue (LTM)
MeiraGTx Financial Valuation Multiples
As of June 18, 2026, MeiraGTx has market cap of $964M and EV of $980M.
MeiraGTx has a P/E ratio of (7.0x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified MeiraGTx Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


MeiraGTx Margins & Growth Rates
MeiraGTx decreased revenue by 39% and EBITDA by 104% in the last fiscal year.
In the most recent fiscal year, MeiraGTx reported gross margin of 94%, EBITDA margin of (110%), and net margin of (140%).
MeiraGTx Margins
MeiraGTx Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
MeiraGTx Operational KPIs
MeiraGTx's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.4M for the same period.
MeiraGTx's Rule of 40 is (32%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
MeiraGTx's Rule of X is (91%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
MeiraGTx Competitors
MeiraGTx competitors include Akums Drugs and Pharma, ACROBiosystems, TchaikaPharma, Xencor, Mega Lifesciences, ARS Pharmaceuticals, SPIMACO - ADDWAEIH, Daewoong Pharmaceutical, GuangYuYuan Chinese and China TCM.
Most MeiraGTx public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 1.7x | 1.7x | 11.9x | 13.6x | |||
| 6.2x | 5.5x | 21.7x | 20.0x | |||
| 25.3x | - | 162.4x | - | |||
| 5.4x | 6.8x | (14.4x) | (3.4x) | |||
| 1.8x | 1.8x | 8.2x | 8.1x | |||
| 10.4x | 7.7x | (5.2x) | - | |||
| 2.6x | 2.6x | 10.9x | 12.1x | |||
| 1.4x | 1.4x | 8.4x | 8.7x | |||
This data is available for Pro users. Sign up to see all MeiraGTx competitors and their valuation data. Start Free Trial | ||||||
MeiraGTx VC Funding History
Before going public, MeiraGTx raised $8M in total equity funding, across 2 rounds.
Last private valuation of MeiraGTx was $65M, after raising $5M in March 2018 from Essex Bio-Technology.
MeiraGTx Funding Rounds
Acquisitions by MeiraGTx
MeiraGTx has acquired 2 companies to date.
Last acquisition by MeiraGTx was on October 17th 2019. MeiraGTx acquired MeiraGTx for $1M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by MeiraGTx
| Description | MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union. | - |
| HQ Country | - | |
| HQ City | Amsterdam | - |
| Deal Date | 17 Oct 2019 | 5 Oct 2018 |
| Valuation | $1M | $24M |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all MeiraGTx acquisitions and their M&A valuation multiples. Start Free Trial | ||
Investments by MeiraGTx
MeiraGTx has invested in 1 company to date.
Latest investment by MeiraGTx was on September 30th 2025. MeiraGTx invested in Hologen Neuro AI in their $30M Strategic investment round (EV/Revenue multiple available to Pro users).
Latest Investments by MeiraGTx
| Description | Hologen Neuro AI is a joint venture between MeiraGTx and Hologen developing AAV-GAD gene therapies for neurological disorders. London and New York-based, the company advances clinical trials for Parkinson's disease treatment via adeno-associated virus vectors expressing GAD enzyme. Hologen Neuro AI's platform targets GABAergic neurons to restore motor function. Phase 1 studies report safety in 20 patients with dosing at multiple brain sites. |
| HQ Country | |
| HQ City | London |
| Deal Date | 30 Sep 2025 |
| Round | Strategic investment |
| Raised | $30M |
| Investors | MeiraGTx |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all MeiraGTx investments and their VC round multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout MeiraGTx
| When was MeiraGTx founded? | MeiraGTx was founded in 2018. |
| Where is MeiraGTx headquartered? | MeiraGTx is headquartered in United Kingdom. |
| How many employees does MeiraGTx have? | As of today, MeiraGTx has over 425 employees. |
| Who is the CEO of MeiraGTx? | MeiraGTx's CEO is Alexandria Forbes. |
| Is MeiraGTx publicly listed? | Yes, MeiraGTx is a public company listed on Nasdaq. |
| What is the stock symbol of MeiraGTx? | MeiraGTx trades under MGTX ticker. |
| When did MeiraGTx go public? | MeiraGTx went public in 2018. |
| Who are competitors of MeiraGTx? | MeiraGTx main competitors include Akums Drugs and Pharma, ACROBiosystems, TchaikaPharma, Xencor, Mega Lifesciences, ARS Pharmaceuticals, SPIMACO - ADDWAEIH, Daewoong Pharmaceutical, GuangYuYuan Chinese, China TCM. |
| What is the current market cap of MeiraGTx? | MeiraGTx's current market cap is $964M. |
| What is the current revenue of MeiraGTx? | MeiraGTx's last 12 months revenue is $67M. |
| What is the current revenue growth of MeiraGTx? | MeiraGTx revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of MeiraGTx? | Current revenue multiple of MeiraGTx is 14.7x. |
| Is MeiraGTx profitable? | No, MeiraGTx is not profitable. |
| What is the current net income of MeiraGTx? | MeiraGTx's last 12 months net income is ($138M). |
| How many companies MeiraGTx has acquired to date? | As of June 2026, MeiraGTx has acquired 2 companies. |
| What was the largest acquisition by MeiraGTx? | $24M acquisition of Vector Neurosciences on 5th October 2018 was the largest M&A MeiraGTx has done to date. |
| What companies MeiraGTx acquired? | MeiraGTx acquired Vector Neurosciences and MeiraGTx. |
| In how many companies MeiraGTx has invested to date? | As of June 2026, MeiraGTx has invested in 1 company. |
| What was the last MeiraGTx investment? | On 30th September 2025 MeiraGTx invested in Hologen Neuro AI, participating in a $30M Strategic investment round. |
| In what companies MeiraGTx invested in? | MeiraGTx invested in Hologen Neuro AI. |
See public comps similar to MeiraGTx
Lists including MeiraGTx
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
